应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
09688 再鼎医药
休市中 05-03 16:09:00
12.800
-0.860
-6.30%
最高
13.480
最低
12.400
成交量
352.70万
今开
13.380
昨收
13.660
日振幅
7.91%
总市值
126.99亿
流通市值
126.99亿
总股本
9.92亿
成交额
4,514万
换手率
0.36%
流通股本
9.92亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
再鼎医药(09688)股价下跌8.199%,现价港币$12.54
阿斯达克财经 · 05-03 10:55
再鼎医药(09688)股价下跌8.199%,现价港币$12.54
再鼎医药(09688)下跌5.12%,报12.96元/股
金融界 · 05-03 09:51
再鼎医药(09688)下跌5.12%,报12.96元/股
再鼎医药盘中异动 早盘股价大跌5.12%报12.961港元
自选股智能写手 · 05-03 09:51
再鼎医药盘中异动 早盘股价大跌5.12%报12.961港元
再鼎医药上涨3.81%,报16.505美元/股
金融界 · 05-02 21:34
再鼎医药上涨3.81%,报16.505美元/股
再鼎医药05月02日主力资金流入470万元 连续5日加仓
自选股智能写手 · 05-02 16:16
再鼎医药05月02日主力资金流入470万元 连续5日加仓
南向资金4月30日净买入再鼎医药76.02万股 连续3日增持
自选股智能写手 · 05-02 09:30
南向资金4月30日净买入再鼎医药76.02万股 连续3日增持
再鼎医药下跌2.05%,报15.79美元/股
金融界 · 05-01
再鼎医药下跌2.05%,报15.79美元/股
再鼎医药上涨2.51%,报16.31美元/股
金融界 · 04-29
再鼎医药上涨2.51%,报16.31美元/股
再鼎医药04月29日获主力加仓953万元 环比增加790.65%
自选股智能写手 · 04-29
再鼎医药04月29日获主力加仓953万元 环比增加790.65%
再鼎医药:2024年第一季度业绩将于5月8日美国东部时间、5月9日香港时间发布
金融界港股 · 04-26
再鼎医药:2024年第一季度业绩将于5月8日美国东部时间、5月9日香港时间发布
再鼎医药下跌2.27%,报15.31美元/股
金融界 · 04-25
再鼎医药下跌2.27%,报15.31美元/股
再鼎医药上涨5.03%,报15.88美元/股
金融界 · 04-24
再鼎医药上涨5.03%,报15.88美元/股
再鼎医药:朱彤出任大中华区首席商务官
中国网财经 · 04-24
再鼎医药:朱彤出任大中华区首席商务官
再鼎医药盘中异动 股价大涨5.07%
自选股智能写手 · 04-23
再鼎医药盘中异动 股价大涨5.07%
总裁离职!再鼎医药发生高层换血,“2025年前实现盈利”目标能否实现?
金融界 · 04-23
总裁离职!再鼎医药发生高层换血,“2025年前实现盈利”目标能否实现?
新人 | 再鼎医药大中华区总裁离职
健识局 · 04-22
新人 | 再鼎医药大中华区总裁离职
再鼎医药首席商务官梁怡离职:朱彤接任大中华区新职位
和讯网 · 04-22
再鼎医药首席商务官梁怡离职:朱彤接任大中华区新职位
据界面新闻前先声再明首席运营官、先声药业高级副总裁朱彤今日加入再鼎医药担任大中华区首席商务官公司现任再鼎医药首席商务官兼大中华区总裁梁怡将于4月30日离开再鼎医药。同日再鼎医药确认前述消息但没有对公司这一岗位的人事变动做出进一步解释。
智通财经 · 04-22
据界面新闻前先声再明首席运营官、先声药业高级副总裁朱彤今日加入再鼎医药担任大中华区首席商务官公司现任再鼎医药首席商务官兼大中华区总裁梁怡将于4月30日离开再鼎医药。同日再鼎医药确认前述消息但没有对公司这一岗位的人事变动做出进一步解释。
再鼎医药大中华区首席商务官梁怡月底离任,前先声再明首席运营官朱彤接任
界面 · 04-22
再鼎医药大中华区首席商务官梁怡月底离任,前先声再明首席运营官朱彤接任
再鼎医药盘中异动 早盘股价大涨5.02%报11.321港元
自选股智能写手 · 04-22
再鼎医药盘中异动 早盘股价大涨5.02%报11.321港元
加载更多
公司概况
公司名称:
再鼎医药
所属市场:
SEHK
上市日期:
--
主营业务:
Zai Lab Ltd是一家主要从事生物制药的控股公司该公司致力于发现或许可、开发和商业化专有疗法,以解决中国市场中大量未满足医疗需求的领域,包括肿瘤学、自身免疫和传染病。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括Niraparib(ZL-2306)、ZL-2103和ZL-1101等。
发行价格:
--
{"stockData":{"symbol":"09688","market":"HK","secType":"STK","nameCN":"再鼎医药","latestPrice":12.8,"timestamp":1714723740033,"preClose":13.66,"halted":0,"volume":3526954,"delay":0,"floatShares":992087430,"shares":992087430,"eps":-2.7050617,"marketStatus":"休市中","marketStatusCode":7,"change":-0.86,"latestTime":"05-03 16:09:00","open":13.38,"high":13.48,"low":12.4,"amount":45143898,"amplitude":0.079063,"askPrice":12.8,"askSize":42200,"bidPrice":12.76,"bidSize":25600,"shortable":3,"etf":0,"ttmEps":-2.7050616001187473,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"listingDate":1601222400000,"adjPreClose":13.66,"openAndCloseTimeList":[[1714699800000,1714708800000],[1714712400000,1714723200000]],"volumeRatio":0.9182235145321993,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09688/","defaultTab":"news","newsList":[{"id":"2432584990","title":"再鼎医药(09688)股价下跌8.199%,现价港币$12.54","url":"https://stock-news.laohu8.com/highlight/detail?id=2432584990","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2432584990?lang=zh_cn&edition=full","pubTime":"2024-05-03 10:55","pubTimestamp":1714704900,"startTime":"0","endTime":"0","summary":"[下跌股]再鼎医药(09688) 股价在上午10:55比前收市价下跌8.199%,现股价为港币$12.54。至目前为止,今日最高价为$13.48,而最低价为$12.54。总成交量为168.378万股,总成交金额为港币$2.182千万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2405031077/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2432996094","title":"再鼎医药(09688)下跌5.12%,报12.96元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2432996094","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2432996094?lang=zh_cn&edition=full","pubTime":"2024-05-03 09:51","pubTimestamp":1714701117,"startTime":"0","endTime":"0","summary":"5月3日,再鼎医药(09688)盘中下跌5.12%,截至09:51,报12.96元/股,成交1013.43万元。再鼎医药有限公司主要业务是研发和销售针对肿瘤、自身免疫性疾病、感染性疾病和中枢神经系统疾病的创新药物,以满足全球患者的医疗需求。关键经营数据方面,公司以其强大的研发能力和全球化运营策略,致力于成为全球领先的生物制药公司。截至2023年年报,再鼎医药营业总收入18.89亿元、净利润-23.7亿元。5月9日,再鼎医药将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/03095140513414.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432999179","title":"再鼎医药盘中异动 早盘股价大跌5.12%报12.961港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432999179","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432999179?lang=zh_cn&edition=full","pubTime":"2024-05-03 09:51","pubTimestamp":1714701114,"startTime":"0","endTime":"0","summary":"2024年05月03日早盘09时51分,再鼎医药股票出现异动,股价急速跳水5.12%。截至发稿,该股报12.961港元/股,成交量76.794万股,换手率0.08%,振幅4.10%。资金方面,该股资金流入455.125万港元,流出326.526万港元。再鼎医药股票所在的生物技术行业中,整体涨幅为0.37%。其相关个股中,美因基因、和铂医药-B、昭衍新药涨幅较大,振幅较大的相关个股有圣诺医药-B、美因基因、药明合联,振幅分别为16.28%、12.83%、9.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405030951547925b9ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405030951547925b9ad&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432609050","title":"再鼎医药上涨3.81%,报16.505美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2432609050","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2432609050?lang=zh_cn&edition=full","pubTime":"2024-05-02 21:34","pubTimestamp":1714656865,"startTime":"0","endTime":"0","summary":"5月2日,再鼎医药(ZLAB)开盘上涨3.81%,截至21:34,报16.505美元/股,成交149.98万美元。财务数据显示,截至2023年12月31日,再鼎医药收入总额2.67亿美元,同比增长24.03%;归母净利润-3.35亿美元,同比增长24.51%。大事提醒:5月8日,再鼎医药将于(美东)盘后披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/05/02213440511334.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432623698","title":"再鼎医药05月02日主力资金流入470万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2432623698","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432623698?lang=zh_cn&edition=full","pubTime":"2024-05-02 16:16","pubTimestamp":1714637793,"startTime":"0","endTime":"0","summary":"05月02日, 再鼎医药股价涨5.08%,报收13.66元,成交金额4336万元,换手率0.33%,振幅9.23%,量比0.78。再鼎医药今日主力资金净流入470万元,连续5日净流入,上一交易日主力净流入213万元,今日环比增加120.66%。近一年数据显示,该股主力连续5日净流入后,次日上涨概率为55.56%,平均涨幅为3.80%。该股近5个交易日上涨12.44%,主力资金累计净流入2030万元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流入3216万元,其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050216171787ca405f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050216171787ca405f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432695859","title":"南向资金4月30日净买入再鼎医药76.02万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2432695859","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432695859?lang=zh_cn&edition=full","pubTime":"2024-05-02 09:30","pubTimestamp":1714613426,"startTime":"0","endTime":"0","summary":"4月30日, 南向资金增持再鼎医药76.02万股,连续3日增持。截止当日收盘,港股通共持有再鼎医药8521.69万股,占流通股8.58%。再鼎医药近5个交易日上涨7.62%,港股通累计增持43.85万股;近20个交易日上涨0.78%,港股通累计增持66.41万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050209325387c94b38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050209325387c94b38&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432170583","title":"再鼎医药下跌2.05%,报15.79美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2432170583","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2432170583?lang=zh_cn&edition=full","pubTime":"2024-05-01 02:51","pubTimestamp":1714503083,"startTime":"0","endTime":"0","summary":"5月1日,再鼎医药(ZLAB)盘中下跌2.05%,截至02:51,报15.79美元/股,成交376.1万美元。财务数据显示,截至2023年12月31日,再鼎医药收入总额2.67亿美元,同比增长24.03%;归母净利润-3.35亿美元,同比增长24.51%。大事提醒:5月8日,再鼎医药将于(美东)盘后披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/05/01025140501393.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431891950","title":"再鼎医药上涨2.51%,报16.31美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431891950","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431891950?lang=zh_cn&edition=full","pubTime":"2024-04-29 23:37","pubTimestamp":1714405071,"startTime":"0","endTime":"0","summary":"4月29日,再鼎医药(ZLAB)盘中上涨2.51%,截至23:37,报16.31美元/股,成交140.22万美元。财务数据显示,截至2023年12月31日,再鼎医药收入总额2.67亿美元,同比增长24.03%;归母净利润-3.35亿美元,同比增长24.51%。大事提醒:5月8日,再鼎医药将于(美东)盘后披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/29233740478908.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431500702","title":"再鼎医药04月29日获主力加仓953万元 环比增加790.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431500702","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431500702?lang=zh_cn&edition=full","pubTime":"2024-04-29 16:16","pubTimestamp":1714378561,"startTime":"0","endTime":"0","summary":"04月29日, 再鼎医药股价跌0.48%,报收12.56元,成交金额5152万元,换手率0.41%,振幅3.49%,量比0.87。再鼎医药今日主力资金净流入953万元,连续3日净流入,上一交易日主力净流入107万元,今日环比增加790.65%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为57.14%,平均涨幅为2.84%。该股近5个交易日上涨9.97%,主力资金累计净流入1082万元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流入2597万元,其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291616508b60fcab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291616508b60fcab&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430723247","title":"再鼎医药:2024年第一季度业绩将于5月8日美国东部时间、5月9日香港时间发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2430723247","media":"金融界港股","top":-1,"share":"https://www.laohu8.com/m/news/2430723247?lang=zh_cn&edition=full","pubTime":"2024-04-26 16:52","pubTimestamp":1714121573,"startTime":"0","endTime":"0","summary":"金融界4月26日消息,再鼎医药的董事会评审委员会将于2024年5月8日 /2024年5月9日审理并批准公司及其附属公司于2024年3月31日止的三个月未经审核季度业绩。再鼎医药的管理层计划在业绩公告发布后,于2024年5月9日上午8:00/2024年5月9日下午8:00,举行业绩电话会议和网络直播,讨论第一季度业绩并回答问题。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/26165240431924.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430228549","title":"再鼎医药下跌2.27%,报15.31美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430228549","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430228549?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:34","pubTimestamp":1714052096,"startTime":"0","endTime":"0","summary":"4月25日,再鼎医药(ZLAB)开盘下跌2.27%,截至21:34,报15.31美元/股,成交30.57万美元。财务数据显示,截至2023年12月31日,再鼎医药收入总额2.67亿美元,同比增长24.03%;归母净利润-3.35亿美元,同比增长24.51%。大事提醒:5月8日,再鼎医药将于(美东)盘后披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/25213440414146.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429456197","title":"再鼎医药上涨5.03%,报15.88美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429456197","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2429456197?lang=zh_cn&edition=full","pubTime":"2024-04-24 21:30","pubTimestamp":1713965432,"startTime":"0","endTime":"0","summary":"4月24日,再鼎医药(ZLAB)开盘上涨5.03%,截至21:30,报15.88美元/股,成交14.14万美元。财务数据显示,截至2023年12月31日,再鼎医药收入总额2.67亿美元,同比增长24.03%;归母净利润-3.35亿美元,同比增长24.51%。大事提醒:5月8日,再鼎医药将于(美东)盘后披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/24213040392882.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429548068","title":"再鼎医药:朱彤出任大中华区首席商务官","url":"https://stock-news.laohu8.com/highlight/detail?id=2429548068","media":"中国网财经","top":-1,"share":"https://www.laohu8.com/m/news/2429548068?lang=zh_cn&edition=full","pubTime":"2024-04-24 17:36","pubTimestamp":1713951377,"startTime":"0","endTime":"0","summary":"中国网财经4月24日讯日前,中国网财经从再鼎医药处获悉,先声再明原首席运营官朱彤将加入公司,担任大中华区首席商务官。而公司原首席商务官兼大中华区总裁梁怡将于4月底离任。公开资料显示,在加入再鼎医药之前,朱彤曾在先声药业、阿斯利康中国、赛诺菲等知名企业任职,有丰富的跨国药企工作经验。再鼎医药作为创新药企,产品主要聚焦肿瘤、自身免疫疾病、感染性疾病和中枢神经系统疾病等领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404243057722115.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404243057722115.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429615643","title":"再鼎医药盘中异动 股价大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429615643","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429615643?lang=zh_cn&edition=full","pubTime":"2024-04-23 14:44","pubTimestamp":1713854658,"startTime":"0","endTime":"0","summary":"2024年04月23日下午盘14时44分,再鼎医药股票出现波动,股价快速上涨5.07%。截至发稿,该股报12.021港元/股,成交量383.25万股,换手率0.39%,振幅5.59%。再鼎医药股票所在的生物技术行业中,整体涨幅为1.38%。其相关个股中,北海康成-B、来凯医药-B、康诺亚-B涨幅较大,振幅较大的相关个股有北海康成-B、来凯医药-B、康诺亚-B,振幅分别为31.25%、20.04%、11.15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231444207a54c246&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231444207a54c246&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429135029","title":"总裁离职!再鼎医药发生高层换血,“2025年前实现盈利”目标能否实现?","url":"https://stock-news.laohu8.com/highlight/detail?id=2429135029","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2429135029?lang=zh_cn&edition=full","pubTime":"2024-04-23 10:45","pubTimestamp":1713840333,"startTime":"0","endTime":"0","summary":"4月22日消息,原先声药业副总裁朱彤加入再鼎医药担任大中华区首席商务官,现任首席商务官兼大中华区总裁梁怡将于4月30日离职。再鼎医药已向媒体确认了这一消息。值得注意的是,作为中国创新药企的代表,再鼎医药此时正处于向“2025年前实现盈利”之目标全力加速的关键时刻,因而此时的高层变动格外引发市场关注。他在阿斯利康中国担任副总裁期间,负责心血管、肾脏及代谢事业部。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/23104540361213.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429410928","title":"新人 | 再鼎医药大中华区总裁离职","url":"https://stock-news.laohu8.com/highlight/detail?id=2429410928","media":"健识局","top":-1,"share":"https://www.laohu8.com/m/news/2429410928?lang=zh_cn&edition=full","pubTime":"2024-04-22 20:09","pubTimestamp":1713787768,"startTime":"0","endTime":"0","summary":"一则“再鼎医药首席商务官兼大中华区总裁梁怡将于4月30日离职”的消息在业界广为流传。2018年6月,梁怡加盟再鼎医药,出任公司首席商务官、兼任大中华区总裁。任职期间,梁怡帮助再鼎医药搭建商业化团队,则乐、爱普盾、擎乐、纽再乐等一批产品获批上市。对于梁怡未来工作的去向,再鼎医药表示公司不知情。4月22日,前先声药业首席运营官、先声药业高级副总裁朱彤宣布加盟再鼎医药,担任大中华区首席商务官,接替梁怡的职位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404222026278b46208a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404222026278b46208a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429923096","title":"再鼎医药首席商务官梁怡离职:朱彤接任大中华区新职位","url":"https://stock-news.laohu8.com/highlight/detail?id=2429923096","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2429923096?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:20","pubTimestamp":1713781245,"startTime":"0","endTime":"0","summary":"快讯正文【再鼎医药商业化团队搭建者梁怡离任,朱彤接替首席商务官】再鼎医药宣布,前首席商务官兼大中华区总裁梁怡将于4月30日正式离职,其职责将由先声药业高级副总裁朱彤接替。朱彤的加入预示着再鼎医药在商业化道路上的全新布局。梁怡在任期间成功搭建了公司商业化团队,为再鼎医药的商业发展奠定基础。尽管再鼎医药未对此次人事变动提供详细理由,但梁怡的离任及朱彤的加入或将为公司带来新的商业策略与市场机遇。下载和讯APP查看快讯,体验更佳>>","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042220421087a170bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042220421087a170bf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429694384","title":"据界面新闻前先声再明首席运营官、先声药业高级副总裁朱彤今日加入再鼎医药担任大中华区首席商务官公司现任再鼎医药首席商务官兼大中华区总裁梁怡将于4月30日离开再鼎医药。同日再鼎医药确认前述消息但没有对公司这一岗位的人事变动做出进一步解释。","url":"https://stock-news.laohu8.com/highlight/detail?id=2429694384","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429694384?lang=zh_cn&edition=full","pubTime":"2024-04-22 17:41","pubTimestamp":1713778913,"startTime":"0","endTime":"0","summary":"据界面新闻前先声再明首席运营官、先声药业高级副总裁朱彤今日加入再鼎医药担任大中华区首席商务官公司现任再鼎医药首席商务官兼大中华区总裁梁怡将于4月30日离开再鼎医药。同日再鼎医药确认前述消息但没有对公司这一岗位的人事变动做出进一步解释。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042217415587a0dba9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042217415587a0dba9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429921199","title":"再鼎医药大中华区首席商务官梁怡月底离任,前先声再明首席运营官朱彤接任","url":"https://stock-news.laohu8.com/highlight/detail?id=2429921199","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2429921199?lang=zh_cn&edition=full","pubTime":"2024-04-22 13:56","pubTimestamp":1713765362,"startTime":"0","endTime":"0","summary":"界面新闻获悉,前先声再明首席运营官、先声药业高级副总裁朱彤今日加入再鼎医药担任大中华区首席商务官,公司现任中华区首席商务官梁怡将于4月30日离开再鼎医药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221356027a54684e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221356027a54684e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429962304","title":"再鼎医药盘中异动 早盘股价大涨5.02%报11.321港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429962304","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429962304?lang=zh_cn&edition=full","pubTime":"2024-04-22 09:56","pubTimestamp":1713750979,"startTime":"0","endTime":"0","summary":"2024年04月22日早盘09时56分,再鼎医药股票出现异动,股价快速上涨5.02%。截至发稿,该股报11.321港元/股,成交量77.51万股,换手率0.08%,振幅4.08%。资金方面,该股资金流入573.323万港元,流出211.466万港元。再鼎医药股票所在的生物技术行业中,整体跌幅为0.35%。其相关个股中,亚盛医药-B、金斯瑞生物科技、创胜集团-B涨幅较大,振幅较大的相关个股有科笛-B、来凯医药-B、金斯瑞生物科技,振幅分别为9.06%、5.97%、5.94%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404220956197a545edc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404220956197a545edc&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":0.0273},{"period":"3month","weight":-0.2711},{"period":"6month","weight":-0.3725},{"period":"1year","weight":-0.5303},{"period":"ytd","weight":-0.4047}],"compareEarnings":[{"period":"1week","weight":0.0467},{"period":"1month","weight":0.1047},{"period":"3month","weight":0.1894},{"period":"6month","weight":0.046},{"period":"1year","weight":-0.0738},{"period":"ytd","weight":0.0838}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"Zai Lab Ltd是一家主要从事生物制药的控股公司该公司致力于发现或许可、开发和商业化专有疗法,以解决中国市场中大量未满足医疗需求的领域,包括肿瘤学、自身免疫和传染病。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括Niraparib(ZL-2306)、ZL-2103和ZL-1101等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.016509},{"month":2,"riseRate":0.5,"avgChangeRate":-0.001648},{"month":3,"riseRate":0,"avgChangeRate":-0.143693},{"month":4,"riseRate":0.75,"avgChangeRate":0.076104},{"month":5,"riseRate":0.25,"avgChangeRate":-0.060959},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.041878},{"month":7,"riseRate":0.666667,"avgChangeRate":0.0492},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.00144},{"month":9,"riseRate":0,"avgChangeRate":-0.186765},{"month":10,"riseRate":0.5,"avgChangeRate":-0.079493},{"month":11,"riseRate":0.75,"avgChangeRate":0.139277},{"month":12,"riseRate":0.5,"avgChangeRate":0.014831}],"exchange":"SEHK","name":"再鼎医药","nameEN":"ZAI LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,09688,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}